When: Next filing or clinical catalyst validates normalized EPS, FCF, pipeline

Then: Deploy 30% of planned incremental

STAY AT 1.0x BENCHMARK WEIGHT; DEPLOY FIRST TRANCHE ONLY ON CONFIRMED PULLBACK TO 146-150

• RSI at 71 with price within $5 of upper Bollinger band and ATR expanded 37% from pre-breakout levels represents a coiled spring near resistance, not healthy consolidation
• Stock at 96% of 52-week high after rallying 19% in one month on Phase 3 melanoma catalyst; market has already priced in the news
• Wolfe Research placed $9.2 billion TAM on vaccine class; analyst community frames $200 as path target but consensus targets remain below that level
• Normalized P/E of 25-28x masks real concerns: $24.6 billion in acquisitions deployed in nine months, negative tangible book value, 128% debt-to-equity
• FCF of $15 billion with $8.4 billion going to dividends leaves only $6.6 billion for debt paydown, buybacks, and capex; $19 billion in net new debt issued over 12 months creates a three-year deleveraging timeline assuming no surprises
• Revolution Medicines received FDA approval for daraxonrasib in pancreatic cancer, a 60,000-patient annual market with limited treatment options where MRK has no comparable asset
• Two consecutive quarters of GAAP losses with balance sheet nearly doubling leverage in nine months represents concentrated risk at a 52-week high
• Pullback to 146-150 is the defined risk envelope; chasing at 153 followed by a normal 5-8% pullback to 140 creates drawdowns that exceed plan design
• Keytruda biosimilar risk expected in 2028 creates post-Keytruda transition funding pressure at exactly the moment when financial flexibility is most constrained
• Moderna collaboration provides validation but the moat is not infinite; concentrating 1.25x overweight at current levels is a crowded trade, not a moat

→ vs aggressive: Entry at 153 versus 148 is not academic—it is the difference between a -3% drawdown that tests conviction and an -8% drawdown that triggers the stop

→ vs aggressive: The stock is up 19% in one month; capital has already rotated into defensives all summer, meaning the macro beta has already been captured, not future appreciation

→ vs aggressive: Waiting for defined entry zones is not a failure of conviction—it is the discipline of risk-adjusted position building; treating 153 as the new floor is an anchoring error

→ vs aggressive: Consensus targets below $200 suggest either the consensus is wrong (30% multiple expansion required) or the catalyst is already priced in—either way risk-reward at 153 is asymmetrically worse than at 130

HOLD with phased deployment: 50-60% of first tranche at 148-150, reserve 40-50% for 146 retest or 152-153 breakout confirmation, cap total exposure at 1.25x with 0.5% NAV stop loss at 146.85

• RSI re-extension to 71 in uptrend is constructive but price sits less than $5 below Bollinger upper band after 12.6% gap-up
• ATR expanded 37% post-breakout—noting volatility repricing rather than contained risk
• Stock at 96% of 52-week high, up 19% in one month with bullish consensus at 7.5/10
• Debt up $19.7B YoY with D/E at 128% but FCF of $15B provides coverage; payout ratio 55%
• 10 EMA at 146.85 and rising toward 149, creating a moving technical target
• Consensus target of 180 implies 18% upside from 153—not fully priced in
• Macro tailwind: 87% probability of no Fed cuts in 2026, 32% probability of hike at September FOMC driving defensive pharma rotation
• Moderna-Keytruda melanoma collaboration widens competitive moat but daraxonrasib in pancreatic creates bounded competitive risk
• 0.21 beta makes MRK a defensive anchor but overconcentration at 52-week highs undermines that benefit
• Deploy first tranche at 148-150 zone (confluence with August 24 intraday low at 150.66) with stop at 146.85 closing basis invalidation

→ vs aggressive: ATR expansion of 37% post-breakout means volatility has repriced higher—cannot use this to argue risk is contained; calling 153 the new floor is a stretch when ATR has expanded by more than $1 per day since August 19

→ vs conservative: The 146 entry target was set when MRK traded lower; waiting for perfect 146 entry when 10 EMA is at 146.85 and rising toward 149 creates a moving technical target and real opportunity cost given defensive sector rotation